Table 1.
Characterization of the SICFAIL study population.
| Variable | All patients (n = 412) | Good outcome (mRS ⩽ 2) (n = 290) | Poor outcome (mRS ⩾ 3) (n = 122) |
|---|---|---|---|
| Demographics | |||
| Age (years) | 70 (59–78) | 66 (57–76) | 76.5 (70–83) |
| Male sex | 261 (63) | 197 (68) | 64 (52) |
| NIHSS | 3 (1–5) | 2 (1–4) | 4 (2–9) |
| ASTRAL score | 18 (16–21) | 17 (15–20) | 21 (18–26) |
| Etiology | |||
| Large artery atherosclerosis | 55 (13) | 39 (13) | 16 (13) |
| Cardioembolism | 121 (30) | 71 (25) | 50 (41) |
| Small artery occlusion | 56 (14) | 45 (16) | 11 (9) |
| Other cause | 14 (3) | 10 (3) | 4 (3) |
| Undetermined | 163 (40) | 125 (43) | 41 (34) |
| Risk factors | |||
| Atrial fibrillation | 98 (24) | 47 (16) | 51 (42) |
| Hypertension | 308 (75) | 202 (70) | 106 (87) |
| Diabetes mellitus | 111 (27) | 65 (23) | 46 (39) |
| Previous stroke | 43 (10) | 25 (9) | 18 (15) |
| Hyperlipidemia | 114 (28) | 81 (28) | 33 (28) |
| Coronary heart disease | 74 (18) | 43 (15) | 31 (25) |
| Heart failure | 29 (7) | 14 (5) | 16 (13) |
| Estimated glomerular filtration rate (mL/min/1.73 m2) | 87 (71–96) | 88 (73–99) | 81 (62–92) |
| Biomarkers | |||
| NT-proBNP (pg/mL) | 276 (89–940) | 188 (65–606) | 753 (303–1991) |
| MR-proANP (pmol/L) | 122 (74–2017) | 101 (69–171) | 198 (119–292) |
| Procalcitonin (ng/mL) | 0.05 (0.03–0.07) | 0.04 (0.03–0.07) | 0.05 (0.03–0.09) |
| Copeptin (pmol/L) | 7.9 (5.3–13.6) | 7.2 (5.0–7.3) | 12 (6.4–23.9) |
| Cortisol (μg/dL) | 21.0 (16.8–25.7) | 20.4 (15.9–24.7) | 22.7 (18.6–27.2) |
| Events during follow-up | |||
| Any stroke | 35 (8.5) | 23 (7.9) | 12 (9.8) |
| Myocardial infarction | 1 (0.2) | 1 (0.3) | 0 |
| Pneumonia requiring rehospitalization | 3 (0.7) | 1 (0.3) | 2 (1.6) |
mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; ASTRAL: Acute Stroke Registry and Analysis of Lausanne; NT-proBNP: N-terminal B-type natriuretic peptide; MR-proANP: mid-regional proatrial natriuretic peptide.
Data are median (quartiles) or n (percent).